SNOA possible playout, Trending, momentum play, if it holds and wins 0.22 then will break out to 0.41, not financial advice.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.89 USD
−4.83 M USD
12.73 M USD
1.32 M
About Sonoma Pharmaceuticals, Inc.
Sector
CEO
Amy M. Trombly
Headquarters
Boulder
Website
Founded
1999
FIGI
BBG000M75YR0
Sonoma Pharmaceuticals, Inc. engages in the development and production of hypochlorous acid (HOCl) products for wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.
SNOA bullishThis stock seems to be gaining some bullish volume and the structure looks ready to shoot up.
$SNOA upside potential Sonoma Pharmaceuticals is a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatological conditions, wound care, animal health care, eye care, nasal care and oral care.
mid term 3,700%Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally.
$SNOABUY AND SELL SETUP
This one is more of a longer term investment.
As it shot up and retraced back down, we're sitting within golden pocket boundary.
I would start buying and buying the dips to average out my price.
Always remember, time is your best friend!
SNOA: $4.35 | Sold Out Shares & Under Valuedwith new products addressing aesthetic industry should recover when volume
starts to kick in
Sonoma's Harsh Treatments It looks like maybe NASDAQ:SNOA has taken a slide past the industry's watchful eye with this one being so oversold... It may be going under, but it's in California, and Arnold likes those kinds of things. I think this stock will try to regain some ground; mostly because of it's insider buys. So
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of SNOA is 2.63 USD — it has increased by 3.14% in the past 24 hours. Watch Sonoma Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Sonoma Pharmaceuticals, Inc. stocks are traded under the ticker SNOA.
SNOA stock has fallen by −4.71% compared to the previous week, the month change is a −16.51% fall, over the last year Sonoma Pharmaceuticals, Inc. has showed a −17.81% decrease.
We've gathered analysts' opinions on Sonoma Pharmaceuticals, Inc. future price: according to them, SNOA price has a max estimate of 17.00 USD and a min estimate of 17.00 USD. Watch SNOA chart and read a more detailed Sonoma Pharmaceuticals, Inc. stock forecast: see what analysts think of Sonoma Pharmaceuticals, Inc. and suggest that you do with its stocks.
SNOA reached its all-time high on Jul 17, 2007 with the price of 72,323.37 USD, and its all-time low was 2.32 USD and was reached on Nov 10, 2023. View more price dynamics on SNOA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
SNOA stock is 6.78% volatile and has beta coefficient of 2.40. Track Sonoma Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Sonoma Pharmaceuticals, Inc. there?
Today Sonoma Pharmaceuticals, Inc. has the market capitalization of 3.52 M, it has decreased by −8.80% over the last week.
Yes, you can track Sonoma Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Sonoma Pharmaceuticals, Inc. is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
SNOA earnings for the last quarter are −0.62 USD per share, whereas the estimation was −0.80 USD resulting in a 22.74% surprise. The estimated earnings for the next quarter are −0.69 USD per share. See more details about Sonoma Pharmaceuticals, Inc. earnings.
Sonoma Pharmaceuticals, Inc. revenue for the last quarter amounts to 3.58 M USD, despite the estimated figure of 3.82 M USD. In the next quarter, revenue is expected to reach 4.06 M USD.
SNOA net income for the last quarter is −610.00 K USD, while the quarter before that showed −1.14 M USD of net income which accounts for 46.63% change. Track more Sonoma Pharmaceuticals, Inc. financial stats to get the full picture.
No, SNOA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 172.00 employees. See our rating of the largest employees — is Sonoma Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sonoma Pharmaceuticals, Inc. EBITDA is −4.12 M USD, and current EBITDA margin is −35.53%. See more stats in Sonoma Pharmaceuticals, Inc. financial statements.
Like other stocks, SNOA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sonoma Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Sonoma Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Sonoma Pharmaceuticals, Inc. stock shows the sell signal. See more of Sonoma Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.